Abstract
Get full access to this article
View all access options for this article.
References
1.AAVLife (2014 ). AAVLife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need . Available at www.aavlife.com/ (accessed
April 9 , 2014
).
2.Baxter International and Chatham Therapeutics (2014 ). Baxter to Acquire Chatham Therapeutics . Available at www.baxter.com/press_room/press_releases/2014/04_02_14_chatham.html (accessed
April 8 , 2014
).
3.Diamyd Medical (2014 ). Diamyd Medical's former sister company secures new financing . Available at www.diamyd.com/docs/pressClips.aspx?section=investor&ClipID=1573276 (accessed
April 9 , 2014
).
4.Friedreich's Ataxia Research Alliance (2014 ). International collaboration advances gene therapy for Friedreich's ataxia . Available at www.marketwatch.com/story/international-collaboration-advances-gene-therapy-for-friedreichs-ataxia-2014-04-06 (accessed
April 9 , 2014
).
5.
Perdomini
M.
,
Belbellaa
B.
,
Monassier
L.
, et al . (2014 ). Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia . Available at www.nature.com/nm/journal/vaop/ncurrent/abs/nm.3510.html (accessed
April 9 , 2014
).
6.PeriphaGen Holdings (2014 ). Form D, filed with U.S. Securities and Esxchange Commission March 31, 2014 . Available at www.sec.gov/Archives/edgar/data/1601176/000160117614000001/xslFormDX01/primary_doc.xml (accessed
April 9 , 2014
).
7.ReGenX Biosciences and AveXis (2014 ). ReGenX Biosciences and AveXis enter into exclusive license agreement for the development of treatments for spinal muscular atrophy using NAV® rAAV9 vectors . Available at http://avexisinc.com/regenx-biosciences-avexis-enter-exclusive/ (accessed
April 8 , 2014
).
8.Spark Therapeutics and Genable (2014 ). Spark Therapeutics and Genable Technologies Announce Collaboration to Advance a Gene Therapy Treatment for a Rare Form of Retinitis Pigmentosa . Available at www.sparktx.com/sites/default/files/fields/press-release/spark-genable-retinitis-pigmentosa.pdf (accessed
April 8 , 2014
).
9.
Tascarella
P.
(2014 ). PeriphaGen raises $6.5 million . Available at www.bizjournals.com/pittsburgh/news/2014/04/01/periphagen-raises-6-5-million.html (accessed
April 8 , 2014
).
10.U.S. Securities and Exchange Commission (2014 ). Form D, Periphagen Holdings Inc., completed by Darren Wolfe, filed March 31, 2014, by Darren Wolfe, CEO . Available at www.sec.gov/Archives/edgar/data/1601176/000160117614000001/xslFormDX01/primary_doc.xml (accessed
April 8 , 2014
).
11.Weill Cornell Medical College (2014 ). Heart disease in mice with fatal genetic disorder cured with gene therapy . Available at http://weill.cornell.edu/news/news/2014/04/heart-disease-in-mice-with-fatal-genetic-disorder-cured-with-gene-therapy-friedreichs-ataxia-ronald-crystal.html (accessed
April 9 , 2014
).